This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Announces Appointment Of Kenneth Pienta, M.D. To Board Of Directors

LEXINGTON, Mass., March 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced the appointment of Kenneth Pienta, M.D. to its Board of Directors. Dr. Pienta currently serves as the Donald S. Coffey Professor of Urology, Professor of Oncology, and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.

"We believe that Ken will add further scientific depth to the Curis Board and will continue to make important contributions to Curis due to his deep experience in oncology patient care as well as his unique understanding of precision therapeutic approaches to cancer treatment," said Chief Executive Officer Dan Passeri. "We have benefited from Ken's deep experience in his role as the head of our clinical and scientific advisory board and an advisor in other strategic matters, and we are delighted to welcome him to our board."

"I am pleased to join the Curis board and look forward to working with the board and management team as we collectively seek to advance Curis towards becoming a leading oncology development company," said Dr. Pienta.

Prior to his appointment at the Johns Hopkins University School of Medicine, Dr. Pienta served as the Associate Vice President for Research, Health Sciences, for the University of Michigan and as the Director of Precision Medicine for the Michigan Center for Translational Pathology from 2008 to 2013.

From 1995 to 2013, Dr. Pienta served as the Director of the Prostate Specialized Program of Research Excellence (SPORE) at The University of Michigan. In this role, Dr. Pienta created a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporated bench research, drug candidate development and clinical application. Dr. Pienta has international expertise in the development of novel chemotherapeutic programs for cancer and has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs